ClinicalTrials.gg
CompletedNCT03849313Updated May 4, 2022

Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

A Phase 1 interventional study of Adalimumab in Healthy Volunteers, sponsored by Alvotech Swiss AG. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-04.

Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study has been designed as a multicentre, randomised, double-blind study of AVT02 in healthy adult subjects. The study will assess the PK, safety and tolerability of AVT02 compared to EU-Humira and US licenced Humira (US-Humira), when administered as a single 40 mg SC dose.

Read the detailed description

AVT02 is being developed as a biosimilar to Humira. EU-Humira and US-Humira have therefore been selected as the active control groups in this study.

This study is designed as a multi-center, randomised, double-blind, 3-arm parallel study of AVT02 compared to EU-Humira and US-Humira in healthy adult subjects. The study is designed to evaluate the PK, safety and tolerability of AVT02 compared to EU-Humira and US-Humira when administered as a single dose (40 mg) SC injection.

Subjects will be randomly assigned with a ratio of 1:1:1 to receive either AVT02 or EU-Humira or US-Humira on a single occasion on study Day 1. Both the site staff assessing the subjects and the subjects themselves will be blinded to the treatments being administered.

The study consists of a screening period, admission and treatment period, assessment period and end of study visit. Subjects will undertake a screening visit between Day -28 and Day -1 to determine eligibility in the study. Those subjects that meet the eligibility criteria will be admitted to the study site on the evening prior to dosing (Day -1) when continued eligibility will be assessed.

On Day 1 prior to dosing, baseline assessments will be performed. Subjects will then be dosed according to the randomization schedule. Following dosing, PK, safety and tolerability assessments will be performed according to the study schedule (Table 6Table 6). Subjects will remain confined to the study site from Day -1 to Day 3 (48 hours post-dose). Subjects will return to the study site on Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 12, Day 15, Day 22, Day 29, Day 36, Day 43, Day 50 and Day 57.

An end of study visit will occur at study Day 64 for final study assessments

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female healthy adult subjects willing to sign a patient information and consent form (PICF) and able to undergo protocol related procedures.
  • Age: 18 to 55 years, inclusive.
  • (BMI): 18.5 to 32.0 kg/m2.
  • No history or evidence of a disorder, condition, or disease that, in the opinion of the investigator would pose a risk to subject safety.
  • Resting supine systolic blood pressure of ≤150 mmHg and diastolic blood pressure of ≤90 mmHg. Other vital signs showing no clinically relevant deviations according to the investigator's judgment.
  • 12-lead recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the investigator.
  • Negative urine drug screen and negative alcohol breath test at screening and admission.

Exclusion criteria

Exclusion Criteria

  • Subjects will be excluded from the study if one or more of the following criterion are applicable:
  • Evidence of pathology
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) used in study.
  • Known history of previous exposure to adalimumab or other anti TNF-alpha molecules.
  • Subjects with a recent (within 6 months of dosing) infection requiring hospitalisation or intravenous antibiotic use.
  • Subjects with a recent (within 4 weeks of dosing) infection requiring oral or systemic antibiotics.
  • Subject with a history of recurrent or chronic infections.
  • Subject has a positive test for tuberculosis (TB) during screening or a known history of active or latent TB, except documented and complete adequate treatment of TB.
  • Having received during the 4 weeks before screening or have the intention to receive vaccination during the study.
  • Participation in a drug study within 60 days or 5 half-lives of the previous drug (if known), whichever is longer, prior to drug administration Note: Only the few inclusion/exclusion criteria are mentioned here. Subjects will be screened and randomized as per the full list of inclusion and exclusion criteria in the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    AVT02 100mg/mL

    Biosimilar Adalimumab AVT02

    Drug: Adalimumab

  • Active comparator
    EU-Humira 100mg/mL

    EU Approved Adalimumab originator Humira

    Drug: Adalimumab

  • Active comparator
    US-Humira 100mg/mL

    US licensed Adalimumab originator Humira

    Drug: Adalimumab

Interventions

  • AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function. Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases

    Also known as: Humira ATC code L04AB04

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve AUC0-t

    Venous blood samples will be collected for measurement of Area under the plasma concentration-time curve (AUC 0-t) of AVT02, US-Humira EU Humira

    Time frame: From baseline to day 64

  2. Maximum serum concentration

    Venous blood samples will be collected for measurement of serum concentration of AVT02, EU Humira, US-Humira

    Time frame: From baseline to day 64

  3. Area under the plasma concentration-time curve AUC0-inf

    Venous blood samples will be collected for measurement of Area under the plasma concentration-time curve (AUC 0-inf) of AVT02, US-Humira EU Humira

    Time frame: From baseline to day 64

Secondary outcomes

  1. Pain, Tenderness, Erythema and Swelling

    The injection sites will be monitored for pain, tenderness, erythema and swelling. Each injection site reaction will be categorised using the Injection Site Intensity Grading Scheme. All four outcome measures mentioned in the title will be measured from this one scheme.

    Time frame: From baseline to over a 64 day period

  2. Anti Drug Antibodies (ADRs)

    Formation of Anti Drug Antibody will be measured through a validated assay.

    Time frame: Baseline to over a 64 day period

  3. Adverse Events

    Adverse events will be coded using MedDRA and grouped by system organ class and preferred term and summarised, by treatment group at the time of onset of the AE. The summary tables will present the number and percentage of total subjects and number of events, by system organ class and by preferred term. Injection related reactions will be listed and summarised by reaction using frequency counts and percentage, by treatment group.

    Time frame: From screening to day 64.

  4. Neutralizing Antibodies (NAbs)

    Formation of neutralizing antibodies measured through a validated system

    Time frame: From screening to day 64.

07

Study locations

3 sites
  • Scientia Clinical Research
    Sydney, New South Wales 2031, Australia
  • Christchurch Clinical Studies Trust Limited
    Christchurch, Chistchurch 8011, New Zealand
  • Auckland Clinical Studies
    Auckland, New Zealand
08

References and documents

Publications

  • Wynne C, Schwabe C, Lemech C, Stroissnig H, Dias R, Sobierska J, Guenzi E, Otto H, Sattar A, Kay R, Haliduola HN, Berti F. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST). Expert Opin Investig Drugs. 2022 Sep;31(9):965-976. doi: 10.1080/13543784.2022.2035359. Epub 2022 Feb 10. PubMed 35107050 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Feb 2020, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2019
First posted
Feb 21, 2019
StartActual
Mar 20, 2019
Primary completionActual
Feb 17, 2020
CompletionActual
Feb 17, 2020
Last update
May 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03849313
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Feb 21, 2019
Start date
Mar 20, 2019
Primary completion
Feb 17, 2020
Completion
Feb 17, 2020
Last update
May 4, 2022

Study contacts

Christian Schwabe
principal investigator · Auckland Clinical Studies Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion